The Global Heart Transplant Market is expected to grow at a CAGR of 11.2% during the forecast period of 2018-2023. The International Heart Transplant Market is a continuously developing market, and there are number of device manufacturers who are involved in the manufacturing and development of the Ventricular access devices and also the total artificial heart. Heart failure occurs when the heart cannot pump enough blood and oxygen to support the organs. Coronary artery disease is the one of the main cause which damages the heart muscle that results in heart failure. Some of the other common causes are high blood pressure, and diabetes.
Some of these companies include SynCardia Systems, LLC, HeartWare International Inc., Apaxis Medical, Inc., Calon Cardio, Optum Inc., Thoratec Corporation, CardiacAssist Inc., CARMAT, TransMedics, Inc., ABIOMED, Jarvik Heart and others. Global Heart Transplant Market report “Global Heart Transplant Market Research Report- Forecast To 2023” summarizes the structure of Heart Transplant industry along with forecast for the next 7 years of the various segments and sub-segments of the Global market.
Download Exclusive Sample Copy @ https://www.marketresearchfuture.com/sample_request/1836 .
The continuous increase in the number of heart failure cases has massively pushed the demand for the heart transplantation procedures. It has definitely had an impact in the revenues generated through the transplantation treatments which are also considered as a gold standard treatment for advanced heart failure. There are many factors which are responsible for the development of body condition that may lead to heart failures; such as cough- especially at night, poor exercise tolerance, shortness of breath, fatigue, and fluid retention among others.
Syncardia System LLC. Is the only company which has received approval from FDA for its Total Artificial Heart. According to the company, “Companion 2” (C2) hospital driver supports patients from implant of the SynCardia temporary Total Artificial Heart. This driver can be replaced with the “Freedom” portable Driver once the patient condition becomes clinically stable. Syncardia currently dominates this segment as there is no competition for their product in the market.
Apart from that, there are number of Ventricular Access devices available in the market. Heartmate Series is an intermediate-to-chronic left ventricular assist device developed by Thoratec Corporation. The company claims that, HeartMate II was developed with the goal of providing up to 10 years of circulatory support for a broad range of advanced heart failure patients. There are few other VAD systems developed by Thoratec Corporation such as PVAD, I VAD pump, and CentriMag.
More than 3,000 people are on the waiting list for the Heart transplant on any given day. However, the number of heart donors is only 2,200 every year. There is a huge gap between the demand of the transplant procedures and the supply for the same. Chances of getting a matching donor and successful heart transplant are very slim for any patient. In this scenario, artificial heart transplant is the best possible chance for the patients for their survival. At this moment, there is only one FDA approved total artificial heart in the market which is manufactured by Syncardia Systems LLC.
HVAD pump, developed by HeartWare International Inc is a miniaturized, centrifugal pump capable of delivering up to 10 liters/minute of blood flow from the heart to the rest of the body. The HeartWare VAS is in clinical trials for both bridge to transplantation and destination therapy.
Jarvik 2000 Heart System is a held in hand system developed by Jarvik Heart. It is a pump, about the size of a C battery. The Jarvik 2000 augments the weakened heart’s blood output to help restore a normal blood flow throughout the body.
Order a Single User Premium 80 Pages Copy Enabled with Tables and Figures is Available @ https://www.marketresearchfuture.com/checkout?currency=one_user-USD&report_id=1836 .
There is another noticeable development in the heart transplant business is the introduction of the OCS Heart Protable perfusion and monitopring system by TransMedics Inc. This system is the answer to the current cold storage heart preservation method, which increases the processing time and reduces transplantation ooutcome. OCS Heart System is believed to overcome these challenges and significantly improve patient outcomes, increase transplantation volume, and most importantly it can reduce the cost of the patient care. However, this system is not yet approved in United States, and is majorly used in the leading centers in Europe and Australia.
Artificial heart transplant has emerged as a boon for the people in need for the heart transplant. It has created a hope for the patients who are desperately waiting for the heart transplant. Syncardia Systems Has played a humongous part in this revolutionary change in the treatment options for this severely critical procedure of heart transplant. Unfortunately, this procedure is currently being used less than 50 times per year as a bridge to heart transplant. According to the sources, there are at least 4 total artificial hearts under development. Hopefully, these new developments in the total artificial heart segment will counter all the difficulties in heart transplantation.
Major TOC Heart Transplant Market:
1 Report Prologue
2 Market Introduction
2.2 Scope of Study
2.3 Research Objective
2.4 Assumptions & Limitations
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
Ask Questions to Expertise @ https://www.marketresearchfuture.com/enquiry/1836 .
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar,
Pune – 411028
Phone: +1 646 845 9312